Alisa S Wolberg

Duke University

$13,659,847

Attributed

$24,967,055

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.3M · FY2005–25

$5M$3.8M$2.5M$1.3M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$24,967,055 · 16

By mechanism

R01$15,275,874 · 6

U01$4,245,314 · 1

R33$1,967,631 · 1

R61$1,372,686 · 1

T32$1,162,933 · 2

K01$492,419 · 1

Top collaborators

Most similar at Duke University

Same institution · by research overlap

Gowthami M Arepally$11,531,413
Douglas Brock Cines$21,888,352
Lubica Rauova$2,618,913
Bastiaan Driehuys$13,649,417
Victor F. Tapson$1,539,257

Others in their field

Top investigators on “Coagulation Process”

Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
Daniel F Hanley · Johns Hopkins University$44,193,814
Steven Kyle Grinspoon · Massachusetts General Hospital$22,843,024
Pamela Susan Douglas · Duke University$22,843,024
Mortimer Poncz · University Of Pennsylvania$22,637,344
Carl W White · National Jewish Health$19,202,369

Research focus

Coagulation ProcessThrombosisBlood CoagulationThrombinProteinsBiologicalVenous ThrombosisThrombusPathway InteractionsFibrinVenousInnovationBloodPlasmaBiologyGeneticFunctional DisorderHemorrhageAffectFibrinogenMediatingPreventPublic HealthStructure

Grant awards (55)

Using genomics and functional biology to understand fibrinogen and factor XIII and their effects on thrombotic diseases$745,002

R01 · FY2025 · HL

Interdisciplinary approach to elucidate modifiers of bleeding phenotype in factor XI deficiency$606,023

R01 · FY2025 · HL · contact PI

Genetic Discovery and Functional Validation to Identify Precursors of Clot Embolization in those with a Deep Vein Thrombosis$625,301

R01 · FY2024 · HL

Interdisciplinary approach to elucidate modifiers of bleeding phenotype in factor XI deficiency$625,071

R01 · FY2024 · HL · contact PI

Mechanisms linking the plasminogen/fibrinogen axis to the pathogenesis of COVID-19$531,940

R01 · FY2024 · HL

Genetic Discovery and Functional Validation to Identify Precursors of Clot Embolization in those with a Deep Vein Thrombosis$636,762

R01 · FY2023 · HL

Fibrinogen and Factor XIII in Venous Thromboembolism$553,768

R01 · FY2023 · HL · contact PI

Mechanisms linking the plasminogen/fibrinogen axis to the pathogenesis of COVID-19$542,806

R01 · FY2023 · HL

Enhancement training for the next generation of translational Ph.D. scientists$265,268

T32 · FY2023 · GM · contact PI

Targeting the Plasminogen Activation System to Limit Pancreatic Cancer Progression and Associated Thrombosis$834,158

U01 · FY2022 · HL

Using genomics and functional biology to understand fibrinogen and its effect on thrombotic and atherosclerotic outcomes$695,502

R01 · FY2022 · HL

Genetic Discovery and Functional Validation to Identify Precursors of Clot Embolization in those with a Deep Vein Thrombosis$640,374

R01 · FY2022 · HL

Model system of oral contraceptive-induced VTE: integrating genomic, transcriptomic, and proteomic discovery with functional biology$626,843

R33 · FY2022 · HL

Fibrinogen and Factor XIII in Venous Thromboembolism$566,163

R01 · FY2022 · HL · contact PI

Mechanisms linking the plasminogen/fibrinogen axis to the pathogenesis of COVID-19$551,675

R01 · FY2022 · HL

Enhancement Training for the Next Generation of Translational Ph.D. Scientists$192,641

T32 · FY2022 · GM · contact PI

Using genomics and functional biology to understand fibrinogen and its effect on thrombotic and atherosclerotic outcomes$72,061

R01 · FY2022 · HL

Targeting the Plasminogen Activation System to Limit Pancreatic Cancer Progression and Associated Thrombosis$844,766

U01 · FY2021 · HL

Using genomics and functional biology to understand fibrinogen and its effect on thrombotic and atherosclerotic outcomes$776,923

R01 · FY2021 · HL

Model system of oral contraceptive-induced VTE: integrating genomic, transcriptomic, and proteomic discovery with functional biology$667,852

R33 · FY2021 · HL

Genetic Discovery and Functional Validation to Identify Precursors of Clot Embolization in those with a Deep Vein Thrombosis$656,756

R01 · FY2021 · HL

Mechanisms linking the plasminogen/fibrinogen axis to the pathogenesis of COVID-19$580,295

R01 · FY2021 · HL

Fibrinogen and Factor XIII in Venous Thromboembolism$566,163

R01 · FY2021 · HL · contact PI

Enhancement Training for the Next Generation of Translational Ph.D. Scientists$179,548

T32 · FY2021 · GM · contact PI

Targeting the Plasminogen Activation System to Limit Pancreatic Cancer Progression and Associated Thrombosis$855,078

U01 · FY2020 · HL

Using genomics and functional biology to understand fibrinogen and its effect on thrombotic and atherosclerotic outcomes$810,978

R01 · FY2020 · HL

Model system of oral contraceptive-induced VTE: integrating genomic, transcriptomic, and proteomic discovery with functional biology$672,936

R33 · FY2020 · HL

Fibrinogen and Factor XIII in Venous Thromboembolism$566,163

R01 · FY2020 · HL · contact PI

Enhancement Training for the Next Generation of Translational Ph.D. Scientists$177,318

T32 · FY2020 · GM · contact PI

Targeting the Plasminogen Activation System to Limit Pancreatic Cancer Progression and Associated Thrombosis$892,860

U01 · FY2019 · HL

Using genomics and functional biology to understand fibrinogen and its effect on thrombotic and atherosclerotic outcomes$764,442

R01 · FY2019 · HL

Model system of oral contraceptive-induced VTE: integrating genomic, transcriptomic, and proteomic discovery with functional biology$672,507

R61 · FY2019 · HL

Fibrinogen and Factor XIII in Venous Thrombosis$376,349

R01 · FY2019 · HL · contact PI

Enhancement Training for the Next Generation of Translational Ph.D. Scientists$175,141

T32 · FY2019 · GM · contact PI

Using genomics and functional biology to understand fibrinogen and its effect on thrombotic and atherosclerotic outcomes$32,274

R01 · FY2019 · HL

Targeting the Plasminogen Activation System to Limit Pancreatic Cancer Progression and Associated Thrombosis$818,452

U01 · FY2018 · HL

Model system of oral contraceptive-induced VTE: integrating genomic, transcriptomic, and proteomic discovery with functional biology$700,179

R61 · FY2018 · HL

Fibrinogen and Factor XIII in Venous Thrombosis$376,349

R01 · FY2018 · HL · contact PI

Enhancement Training for the Next Generation of Translational Ph.D. Scientists$173,017

T32 · FY2018 · GM · contact PI

2018 Hemostasis Gordon Research Conference and Gordon Research Seminar$32,760

R13 · FY2018 · HL · contact PI

Fibrinogen and Factor XIII in Venous Thrombosis$376,349

R01 · FY2017 · HL · contact PI

Fibrinogen and Factor XIII in Venous Thrombosis$376,349

R01 · FY2016 · HL · contact PI

Determinants of Thrombus Structure and Stability$377,831

R56 · FY2014 · HL · contact PI

Cellular Determinants of Fibrin Structure and Stability$310,100

R01 · FY2013 · HL · contact PI

Cellular Determinants of Fibrin Structure and Stability$325,850

R01 · FY2012 · HL · contact PI

Cellular Determinants of Fibrin Structure and Stability$329,254

R01 · FY2011 · HL · contact PI

Cellular Determinants of Fibrin Structure and Stability$329,363

R01 · FY2010 · HL · contact PI

Cellular Determinants of Fibrin Structure and Stability$329,469

R01 · FY2009 · HL · contact PI

Pathophysiology of anti-B2GPI Antibodies in APS$102,911

K01 · FY2008 · AR · contact PI

Pathophysiology of anti-B2GPI Antibodies in APS$100,638

K01 · FY2007 · AR · contact PI

BIOCHEMICAL STUDIES OF BLOOD COAGULATION$375

M01 · FY2007 · RR · contact PI

Pathophysiology of anti-B2GPI Antibodies in APS$98,424

K01 · FY2006 · AR · contact PI

Pathophysiology of anti-B2GPI Antibodies in APS$96,270

K01 · FY2005 · AR

Pathophysiology of anti-B2GPI Antibodies in APS$94,176

K01 · FY2004 · AR

CELLULAR TISSUE FACTOR--REGULATION AND ACTIVITY$39,232

F32 · FY2000 · HL